Research programme: cancer therapeutics - Merck/Cancer Research Technology/iOnctura

Drug Profile

Research programme: cancer therapeutics - Merck/Cancer Research Technology/iOnctura

Alternative Names: Anti-CD73 Ab - CRT/iOnctura/Merck; Anti-CXCL12 Ab - CRT/iOnctura/Merck; Anti-lag Ab - CRT/iOnctura/Merck; selective Pi3Kδ inhibitor - CRT/iOnctura/Merck

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; Merck AG
  • Developer Cancer Research Technology; iOnctura; Merck AG
  • Class Antibodies; Antineoplastics
  • Mechanism of Action 5-Nucleotidase-inhibitors; CD223 antigen inhibitors; Chemokine CXCL12 inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Nov 2017 iOnctura plans a clinical trial for the selective phosphatidylinositol-3 kinase delta inhibitor for Cancer in 2018
  • 20 Jun 2017 iOnctura and Cancer Research Technology enter into collaboration to develop three therapeutics for Cancer
  • 20 Jun 2017 Preclinical trials in Cancer in Switzerland (unspecified route) (iOnctura pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top